comprehensive
Editor’s note: A recording of the event is embedded below.
After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.
advertisement
Featured Speakers
- Irena Melnikova, Ph.D., partner, Pfizer Ventures
- Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
- Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
HHS leader on health, climate change and biopharma emissions
Next article： Activists slam private health insurers over coverage restrictions
Next article： Activists slam private health insurers over coverage restrictions
.png?upscale=true&width=1212&upscale=true&name=vTFET-vaccine-makers-surge-on-bird-flu-fears(3).png)
